DiaMedica Inc. Stock Toronto S.E.
Equities
DMA
CA25253T1075
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
|
Jul. 01 | DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding | CI |
Jun. 27 | Transcript : DiaMedica Therapeutics Inc. - Special Call |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 202M 148M |
---|---|---|---|---|---|
Net income 2024 * | -35M -25.66M | Net income 2025 * | -47M -34.46M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.42
x | P/E ratio 2025 * |
-4.65
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.64% |
Latest transcript on DiaMedica Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- DMAC Stock
- DMA Stock